Base de dados : MEDLINE
Pesquisa : A11.118.290 [Categoria DeCS]
Referências encontradas : 115338 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 11534 ir para página                         

  1 / 115338 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29332224
[Au] Autor:Tong D; Yu M; Guo L; Li T; Li J; Novakovic VA; Dong Z; Tian Y; Kou J; Bi Y; Wang J; Zhou J; Shi J
[Ad] Endereço:Department of Hematology, First Hospital, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, 150001, China.
[Ti] Título:Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients.
[So] Source:Ann Hematol;97(4):605-616, 2018 Apr.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The mechanisms of thrombogenicity in essential thrombocythemia (ET) are complex and not well defined. Our objective was to explore whether phosphatidylserine (PS) exposure on blood cells and endothelial cells (ECs) can account for the increased thrombosis and distinct thrombotic risks among mutational subtypes in ET. Using flow cytometry and confocal microscopy, we found that the levels of PS-exposing erythrocytes, platelets, leukocytes, and serum-cultured ECs were significantly higher in each ET group [JAK2, CALR, and triple-negative (TN) (all P < 0.001)] than those in controls. Among ET patients, those with JAK2 mutations showed higher levels of PS-positive erythrocytes, platelets, neutrophils, and serum-cultured ECs than TN patients or those with CALR mutations, which show similar levels. Coagulation function assays showed that higher levels of PS-positive blood cells and serum-cultured ECs led to markedly shortened coagulation time and dramatically increased levels of FXa, thrombin, and fibrin production. This procoagulant activity could be largely blocked by addition of lactadherin (approx. 70% inhibition). Confocal microscopy showed that the FVa/FXa complex and fibrin fibrils colocalized with PS on ET serum-cultured ECs. Additionally, we found a relationship between D-dimer, prothrombin fragment F1 + 2, and PS exposure. Our study reveals a previously unrecognized link between hypercoagulability and exposed PS on cells, which might also be associated with distinct thrombotic risks among mutational subtypes in ET. Thus, blocking PS-binding sites may represent a new therapeutic target for preventing thrombosis in ET.
[Mh] Termos MeSH primário: Plaquetas/patologia
Endotélio Vascular/patologia
Eritrócitos/patologia
Leucócitos/patologia
Fosfatidilserinas/metabolismo
Trombocitemia Essencial/fisiopatologia
Trombose/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Substituição de Aminoácidos
Plaquetas/metabolismo
Calreticulina/genética
Calreticulina/metabolismo
Células Cultivadas
China/epidemiologia
Endotélio Vascular/metabolismo
Eritrócitos/metabolismo
Feminino
Células Endoteliais da Veia Umbilical Humana/citologia
Células Endoteliais da Veia Umbilical Humana/metabolismo
Seres Humanos
Janus Quinase 2/genética
Janus Quinase 2/metabolismo
Leucócitos/metabolismo
Masculino
Meia-Idade
Mutação
Receptores de Trombopoetina/genética
Receptores de Trombopoetina/metabolismo
Risco
Propriedades de Superfície
Trombocitemia Essencial/genética
Trombocitemia Essencial/metabolismo
Trombocitemia Essencial/patologia
Trombose/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calreticulin); 0 (Phosphatidylserines); 0 (Receptors, Thrombopoietin); 0 (calreticulin, human); 143641-95-6 (MPL protein, human); EC 2.7.10.2 (JAK2 protein, human); EC 2.7.10.2 (Janus Kinase 2)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180115
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-018-3228-6


  2 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29278023
[Au] Autor:Clemente-Suárez VJ; Mielgo-Ayuso J; Quiles JL; Varela-Lopez A; Aranda P
[Ad] Endereço:1 Applied Psychophysiological Research Group, European University of Madrid , Madrid, Spain.
[Ti] Título:Effect of α-tocopherol megadoses on hematologic parameters and antioxidant capacity of rats in an ultraendurance probe.
[So] Source:Physiol Int;104(4):291-300, 2017 Dec 01.
[Is] ISSN:2498-602X
[Cp] País de publicação:Hungary
[La] Idioma:eng
[Ab] Resumo:This study was aimed to analyze the effect of two different megadoses of α-tocopherol (vit E) in the antioxidant activity and red and white blood series of Wistar rats after a 180-min ultraendurance probe. Three groups of 10 rats were analyzed; VEAG: acute administration of a megadoses of 5,000 IU/kg of vit E the day before the probe; VECG: chronic administration of 1,000 IU/kg/day of vit E for 6 days before the probe; CG: placebo administration. VEAG presented white cells, red blood cells, hematocrit, hemoglobin values significantly higher than CG and VECG (p < 0.05). The mean corpuscular hemoglobin and lymphocytes concentrations were significantly higher in the VECG than in the other two groups (p < 0.05). Similarly, VEAG presented a significantly higher vit E blood concentration than VECG and CG (p < 0.05), and VECG than CG (p < 0.05). Finally, we found a significantly positive correlation between trolox equivalent antioxidant capacity (TEAC) and red blood cells concentration (r = 0.374) and a significantly inverse correlation between TEAC and blood lactate concentration (r = -0.365). Our findings suggest that acute vit E megadoses could protect against transitory sport anemia symptoms and increase the white blood cell count in comparison with the chronic dose and control groups after an ultraendurance probe.
[Mh] Termos MeSH primário: Leucócitos/fisiologia
Substâncias para Melhoria do Desempenho/administração & dosagem
Resistência Física/efeitos dos fármacos
Resistência Física/fisiologia
Espécies Reativas de Oxigênio/metabolismo
Corrida/fisiologia
alfa-Tocoferol/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antioxidantes/administração & dosagem
Relação Dose-Resposta a Droga
Eritrócitos/citologia
Eritrócitos/fisiologia
Hematócrito
Leucócitos/citologia
Masculino
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Performance-Enhancing Substances); 0 (Reactive Oxygen Species); H4N855PNZ1 (alpha-Tocopherol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE
[do] DOI:10.1556/2060.104.2017.4.2


  3 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27775924
[Au] Autor:Im SH; Jung Y; Jang Y; Kim SH
[Ad] Endereço:KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea. Biomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea.
[Ti] Título:Poly(L-lactic acid) scaffold with oriented micro-valley surface and superior properties fabricated by solid-state drawing for blood-contact biomaterials.
[So] Source:Biofabrication;8(4):045010, 2016 10 24.
[Is] ISSN:1758-5090
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Most biomaterials composed of biodegradable polymers will contact either accidentally or consistently with blood and this commonly requires both good  mechanical strength and blood compatibility. Despite this demand, current processing methods still make it difficult and complex to simultaneously improve the two properties. To overcome present limitations, the aim of this work is to develop a solid-state drawing which is a novel method for blood-contact biomaterials that can simultaneously improve the two essential factors of mechanical strength and blood compatibility, as well as induce a micro-patterned surface. Solid-state drawn (SSD) poly(L-lactic acid) (PLLA) film significantly maximally increased tensile strength and elastic modulus about ninefold and sixfold, respectively, compared to undrawn film. Furthermore, it was determined that SSD-PLLA film had highly developed molecular orientation, higher crystallinity and surface hydrophobicity. Additionally, the SSD method could greatly reduce roughness of the surface and induce the formation of aligned valleys, forming microstructures on the film surface. The topographical cue delayed hydrolytic degradation and prevented damage on the surface by NaOH of alkali compounds are compared with undrawn film. In energy-dispersive x-ray spectroscopy analysis, the surface of SSD film treated by NaOH was not detected on any ions whereas undrawn film held foreign ions on surface defects. The hemolysis rate of SSD film was considerably decreased with an increase of draw ratio up to 0.2% maximally and SSD film has shown greatly lower platelet adhesion compared to undrawn film in blood-compatibility analysis. Interestingly, one-directional alignment of micro-valley structure on SSD film could promote initial adhesion of human umbilical vein endothelial cells (HUVEC) compared with undrawn film and guide the direction of HUVEC. In conclusion, the newly designed SSD method has shown potential for developing blood-contact biomaterials simply due to great mechanical properties, blood compatibility and an aligned micro-patterned surface.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Poliésteres/química
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/farmacologia
Plaquetas/citologia
Varredura Diferencial de Calorimetria
Adesão Celular/efeitos dos fármacos
Módulo de Elasticidade
Eritrócitos/citologia
Eritrócitos/efeitos dos fármacos
Hemólise/efeitos dos fármacos
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Microscopia de Força Atômica
Espectrometria por Raios X
Propriedades de Superfície
Resistência à Tração
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Polyesters); 459TN2L5F5 (poly(lactide))
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29397599
[Au] Autor:Chen Z; Yang YJ; Li J; Tian XP
[Ad] Endereço:Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
[Ti] Título:[The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].
[So] Source:Zhonghua Nei Ke Za Zhi;57(2):129-133, 2018 Feb 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the clinical features of Takayasu's arteritis (TAK) with glomerulonephropathy and to improve physicians' understanding of this complication in patients with TAK. Clinical data were retrospectively collected including manifestations, laboratory tests, image findings and treatment of 8 patients diagnosed as Takayasu's arteritis with glomerulonephropathy from January 2002 to January 2017 in Peking Union Medical College Hospital. Glomerulonephropathy was confirmed based on percutaneous renal biopsy. There were 6 women and 2 men. The median onset age and median disease duration were 24 (18-37) years and 42 (3-360) months, respectively. Five patients had hypertension. The 24 hour urinary protein was 0.18-14.91 g. Red blood cells and casts in urine were tested among 4 and 2 patients, respectively. Three patients had renal artery stenosis. Three patients demonstrated mesangial proliferative glomerulonephritis, two with IgA nephropathy, two with minimal change disease and one with membranoproliferative glomerulonephritis. Seven patients received glucocorticoid combined with cyclophosphamide therapy (glucocorticoid 40-60 mg/d, prednisone or equivalent; cyclophosphamide 0.4 g/week iv. or cyclophosphamide 0.1 g/d po.). Uninary blood cells removed and 24 hour urinary protein decreased from 1.65 g to 0.90 g after treatment for 12 months in one patient. The other 7 patients were missing. Glomerulonephropathy is occasionally observed among TAK patients. Mesangial proliferative glomerulonephritis is the most common pathological subtype. Glucocorticoid combined with cyclophosphamide therapy could be an optional therapy for Takayasu's arteritis with glomerulonephropathy.
[Mh] Termos MeSH primário: Glomerulonefrite Membranoproliferativa/etiologia
Glomerulonefrite/etiologia
Arterite de Takayasu/patologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Ciclofosfamida/administração & dosagem
Ciclofosfamida/uso terapêutico
Eritrócitos
Feminino
Glomerulonefrite/patologia
Glomerulonefrite por IGA
Glomerulonefrite Membranoproliferativa/patologia
Glucocorticoides/administração & dosagem
Glucocorticoides/uso terapêutico
Seres Humanos
Hipertensão
Masculino
Prednisona/administração & dosagem
Prednisona/uso terapêutico
Arterite de Takayasu/complicações
Arterite de Takayasu/tratamento farmacológico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.02.009


  5 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29407462
[Au] Autor:Zambrano P; Suwalsky M; Jemiola-Rzeminska M; Strzalka K
[Ad] Endereço:Faculty of Chemical Sciences, University of Concepción, Concepción, Chile. Electronic address: pzambranol@udec.cl.
[Ti] Título:Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review.
[So] Source:Chem Biol Interact;283:47-50, 2018 Mar 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Memantine is an NMDA receptor antagonist clinically used for the treatment of moderate to severe Alzheimer's disease. Currently, it is the only NMDA receptor antagonist drug marketed against this disease. Despite the large number of publications regarding its clinical and therapeutic use, studies related to its mechanism of action are still inconclusive. Knowledge of drug interactions with cell membranes may lead to the development of novel drugs for neurodegenerative diseases. The present mini-review aims to give an overview of the latest findings regarding the interaction of memantine with cell membranes, specifically with that of the human erythrocyte.
[Mh] Termos MeSH primário: Membrana Celular/efeitos dos fármacos
Memantina/farmacologia
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
[Mh] Termos MeSH secundário: Doença de Alzheimer/tratamento farmacológico
Doença de Alzheimer/metabolismo
Doença de Alzheimer/patologia
Membrana Celular/metabolismo
Eritrócitos/citologia
Eritrócitos/efeitos dos fármacos
Eritrócitos/metabolismo
Seres Humanos
Memantina/química
Memantina/uso terapêutico
Microscopia Eletrônica de Varredura
Receptores de N-Metil-D-Aspartato/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Receptors, N-Methyl-D-Aspartate); W8O17SJF3T (Memantine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  6 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470719
[Au] Autor:Ballas SK
[Ad] Endereço:Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
[Ti] Título:From total blood exchange to erythrocytapheresis and back to treat complications of sickle cell disease.
[So] Source:Transfusion;57(9):2277-2280, 2017 09.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Erythrocytapheresis is an important procedure in the management of certain complications of sickle cell disease, including acute stroke, stroke prevention, acute chest syndrome, and multiorgan failure. Erythrocytapheresis in sickle cell disease simply entails the removal of the patient's red blood cells containing the abnormal sickle hemoglobin and replacing them with normal red blood cells carrying normal hemoglobin. In these procedures, the patient's plasma is not exchanged but is returned to the patient. Several studies have demonstrated that the plasma of patients with sickle cell disease contains several components that increase blood viscosity and initiate or promote vaso-occlusion. These factors include increased levels of globulins, especially immunoglobulin G, acute-phase reactants, fibrinogen, coagulation factors, inflammatory mediators, and heme in the steady state and increase further during painful crises. This may explain why, in certain complications of sickle cell disease, such as acute chest syndrome, hepatic crisis, and priapism, erythrocytapheresis by itself may not be effective despite repetitive cycles of red blood cell exchange. The use of therapeutic plasma exchange in addition to erythrocytapheresis in these situations seems to be useful in resolving them more efficiently. The role of therapeutic plasma exchange in the management of certain complications of sickle cell disease needs further evaluation. This commentary addresses the role of therapeutic plasma exchange in the management of complications of sickle cell disease.
[Mh] Termos MeSH primário: Anemia Falciforme/terapia
Citaferese/métodos
Transfusão Total/métodos
[Mh] Termos MeSH secundário: Anemia Falciforme/complicações
Viscosidade Sanguínea
Gerenciamento Clínico
Eritrócitos
Seres Humanos
Troca Plasmática/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14154


  7 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773469
[Au] Autor:Xu H; Ärnlöv J; Sandhagen B; Risérus U; Lindholm B; Lind L; Carrero JJ
[Ad] Endereço:Divisions of Renal Medicine and Baxter Novum, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:Lipophilic index, kidney function, and kidney function decline.
[So] Source:Nutr Metab Cardiovasc Dis;26(12):1096-1103, 2016 12.
[Is] ISSN:1590-3729
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Unhealthy dietary fats are associated with faster kidney function decline. The cell membrane composition of phospholipid fatty acids (FAs) is a determinant of membrane fluidity and rheological properties. These properties, which have been linked to kidney damage, are thought to be reflected by the lipophilic index (LI). We prospectively investigated the associations of LI with kidney function and its decline. METHODS AND RESULTS: Observational study from the Prospective Investigation of Vasculature in Uppsala Seniors including 975 men and women with plasma phospholipid FAs composition and cystatin-C estimate glomerular filtration rate (eGFR). Of these, 780 attended re-examination after 5 years, and eGFR changes were assessed. Participants with a 5-year eGFR reduction ≥30% were considered chronic kidney disease (CKD) progressors (n = 198). LI was calculated as the sum of the products of the FA proportions with the respective FAs melting points. Blood rheology/viscosity measurements were performed in a random subsample of 559 subjects at baseline. Increased LI showed a statistically significant but overall weak association with blood, plasma viscosity (both Spearman rho = 0.16, p < 0.01), and erythrocyte deformability (rho = -0.09, p < 0.05). In cross-sectional analyses, LI associated with lower eGFR (regression coefficient 3.00 ml/min/1.73 m 1-standard deviation (SD) increment in LI, 95% CI: -4.31, -1.69, p < 0.001). In longitudinal analyses, LI associated with a faster eGFR decline (-2.13 [95% CI -3.58, -0.69] ml/min/1.73 m , p < 0.01) and with 32% increased odds of CKD progression (adjusted OR 1.32 [95%, CI 1.05-1.65]). CONCLUSIONS: A high LI was associated with lower kidney function, kidney function decline, and CKD progression.
[Mh] Termos MeSH primário: Gorduras na Dieta/efeitos adversos
Rim/fisiopatologia
Insuficiência Renal Crônica/etiologia
[Mh] Termos MeSH secundário: Idoso
Biomarcadores/sangue
Viscosidade Sanguínea
Estudos Transversais
Cistatina C/sangue
Gorduras na Dieta/sangue
Progressão da Doença
Deformação Eritrocítica
Eritrócitos/efeitos dos fármacos
Eritrócitos/metabolismo
Ácidos Graxos/efeitos adversos
Ácidos Graxos/sangue
Feminino
Seres Humanos
Estudos Longitudinais
Masculino
Fluidez de Membrana
Análise Multivariada
Razão de Chances
Fosfolipídeos/efeitos adversos
Fosfolipídeos/sangue
Estudos Prospectivos
Insuficiência Renal Crônica/sangue
Insuficiência Renal Crônica/diagnóstico
Insuficiência Renal Crônica/fisiopatologia
Fatores de Risco
Suécia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (CST3 protein, human); 0 (Cystatin C); 0 (Dietary Fats); 0 (Fatty Acids); 0 (Phospholipids)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  8 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29345907
[Au] Autor:Alvarez-Sala A; López-García G; Attanzio A; Tesoriere L; Cilla A; Barberá R; Alegría A
[Ad] Endereço:Nutrition and Food Science Area, Faculty of Pharmacy, University of Valencia , Avda. Vicente Andrés Estellés s/n, Burjassot, Valencia 46100, Spain.
[Ti] Título:Effects of Plant Sterols or ß-Cryptoxanthin at Physiological Serum Concentrations on Suicidal Erythrocyte Death.
[So] Source:J Agric Food Chem;66(5):1157-1166, 2018 Feb 07.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The eryptotic and hemolytic effects of a phytosterol (PS) mixture (ß-sitosterol, campesterol, stigmasterol) or ß-cryptoxanthin (ß-Cx) at physiological serum concentration and their effect against oxidative stress induced by tert-butylhydroperoxide (tBOOH) (75 and 300 µM) were evaluated. ß-Cryptoxanthin produced an increase in eryptotic cells, cell volume, hemolysis, and glutathione depletion (GSH) without ROS overproduction and intracellular Ca influx. Co-incubation of both bioactive compounds protected against ß-Cx-induced eryptosis. Under tBOOH stress, PS prevented eryptosis, reducing Ca influx, ROS overproduction and GSH depletion at 75 µM, and hemolysis at both tBOOH concentrations. ß-Cryptoxanthin showed no cytoprotective effect. Co-incubation with both bioactive compounds completely prevented hemolysis and partially prevented eryptosis as well as GSH depletion induced by ß-Cx plus tBOOH. Phytosterols at physiological serum concentrations help to prevent pro-eryptotic and hemolytic effects and are promising candidate compounds for ameliorating eryptosis-associated diseases.
[Mh] Termos MeSH primário: beta-Criptoxantina/farmacologia
Eriptose/efeitos dos fármacos
Fitosteróis/farmacologia
[Mh] Termos MeSH secundário: beta-Criptoxantina/sangue
Células Cultivadas
Colesterol/análogos & derivados
Colesterol/farmacologia
Eritrócitos/química
Eritrócitos/efeitos dos fármacos
Glutationa/sangue
Hemólise/efeitos dos fármacos
Seres Humanos
Estresse Oxidativo/efeitos dos fármacos
Sitosteroides/farmacologia
Estigmasterol/farmacologia
terc-Butil Hidroperóxido/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Beta-Cryptoxanthin); 0 (Phytosterols); 0 (Sitosterols); 5L5O665639 (campesterol); 5LI01C78DD (gamma-sitosterol); 955VYL842B (tert-Butylhydroperoxide); 97C5T2UQ7J (Cholesterol); 99WUK5D0Y8 (Stigmasterol); GAN16C9B8O (Glutathione)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b05575


  9 / 115338 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29265183
[Au] Autor:Kulkeaw K; Inoue T; Ishitani T; Nakanishi Y; Zon LI; Sugiyama D
[Ad] Endereço:Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
[Ti] Título:Purification of zebrafish erythrocytes as a means of identifying a novel regulator of haematopoiesis.
[So] Source:Br J Haematol;180(3):420-431, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Zebrafish embryos are useful to study haematopoietic gene function in vertebrates, although lack of antibodies to zebrafish proteins has limited the purification of specific cell populations. Here, we purified primitive zebrafish erythrocytes using 1, 5-bis{[2-(di-methylamino)ethyl]amino}-4, 8-dihydroxyanthracene-9, 10-dione (DRAQ5 ), a DNA-staining fluorescent dye. At 48-h post-fertilization, we sorted small-sized cells from embryos using forward scatter and found that they consisted of DRAQ5 and DRAQ5 populations. DRAQ5 cells contained haemoglobin, lacked myeloperoxidase activity and expressed high levels of embryonic globin (hbae3 and hbbe1.1) mRNA, all characteristics of primitive erythrocytes. Following DRAQ5 analysis of gata1:dsRed transgenic embryos, we purified primitive DRAQ5 dsRed+ erythrocytes from haematopoietic progenitor cells. Using this method, we identified docking protein 2 (Dok2) as functioning in differentiation of primitive erythrocytes. We conclude that DRAQ5 -based flow cytometry enables purification of primitive zebrafish erythrocytes.
[Mh] Termos MeSH primário: Eritrócitos/citologia
Eritrócitos/metabolismo
Hematopoese
[Mh] Termos MeSH secundário: Animais
Biomarcadores
Separação Celular/métodos
Citometria de Fluxo
Regulação da Expressão Gênica
Hematopoese/genética
Imunofenotipagem
Especificidade de Órgãos/genética
Peixe-Zebra
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15048


  10 / 115338 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467350
[Au] Autor:Santos HFD; Campos JF; Santos CMD; Balestieri JBP; Silva DB; Carollo CA; de Picoli Souza K; Estevinho LM; Dos Santos EL
[Ad] Endereço:Research group on Biotechnology and Bioprospecting Applied to Metabolism (GEBBAM), Federal University of Grande Dourados, Rodovia Dourados Itahum, Km 12, 79804-970 Dourados, MS, Brazil. helderspk@gmail.com.
[Ti] Título:Chemical Profile and Antioxidant, Anti-Inflammatory, Antimutagenic and Antimicrobial Activities of Geopropolis from the Stingless Bee Melipona orbignyi.
[So] Source:Int J Mol Sci;18(5), 2017 May 03.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Geopropolis is a resin mixed with mud, produced only by stingless bees. Despite being popularly known for its medicinal properties, few scientific studies have proven its biological activities. In this context, the objective of this study was to determine the chemical composition and antioxidant, anti-inflammatory, antimutagenic and antimicrobial activities of the geopropolis. The hydroalcoholic extract of geopropolis (HEGP) was prepared and its chemical composition determined by high performance liquid chromatography coupled to diode array detector and mass spectrometry (HPLC-DAD-MS). The antioxidant activity was determined by the capture of free radicals and inhibition of lipid peroxidation in human erythrocytes. The anti-inflammatory activity was evaluated by the inhibition of the hyaluronidase enzyme and the antimutagenic action was investigated in colonies. The antimicrobial activities were determined against bacteria and yeasts, isolated from reference strains and hospital origin. The chemical composition of HEGP included flavonoids, derivatives of glycosylated phenolic acids and terpenoids. HEGP showed high antioxidant activity, it inhibited the activity of the inflammatory enzyme hyaluronidase and reduced the mutagenic effects in . In relation to the antimicrobial activity, it promoted the death of all microorganisms evaluated. In conclusion, this study reveals for the first time the chemical composition of the HEGP of and demonstrates its pharmacological properties.
[Mh] Termos MeSH primário: Anti-Infecciosos
Anti-Inflamatórios
Antioxidantes
Abelhas/química
Própole
[Mh] Termos MeSH secundário: Animais
Anti-Infecciosos/química
Anti-Infecciosos/farmacologia
Anti-Inflamatórios/química
Anti-Inflamatórios/farmacologia
Antioxidantes/química
Antioxidantes/farmacologia
Bactérias/efeitos dos fármacos
Cromatografia Líquida de Alta Pressão
Eritrócitos/efeitos dos fármacos
Metanossulfonato de Etila/farmacologia
Flavonoides/análise
Radicais Livres/análise
Seres Humanos
Hialuronoglucosaminidase/efeitos dos fármacos
Hidroxibenzoatos/análise
Peroxidação de Lipídeos/efeitos dos fármacos
Espectrometria de Massas
Mutagênicos
Própole/química
Própole/farmacologia
Saccharomyces cerevisiae/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Flavonoids); 0 (Free Radicals); 0 (Hydroxybenzoates); 0 (Mutagens); 29656-58-4 (phenolic acid); 9009-62-5 (Propolis); 9H154DI0UP (Ethyl Methanesulfonate); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE



página 1 de 11534 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde